

Luis L Ostrosky-Zeichner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4686312/publications.pdf>

Version: 2024-02-01

135
papers

20,408
citations

34016

52
h-index

18606

119
g-index

137
all docs

137
docs citations

137
times ranked

13013
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 48, 503-535.	2.9	2,644
2	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, e1-e50.	2.9	2,489
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
4	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, 409-417.	2.9	1,258
5	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. <i>Lancet</i> , The, 2007, 369, 1519-1527.	6.3	1,185
6	Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2007, 45, 883-893.	2.9	1,115
7	Multicenter Clinical Evaluation of the (1->3) β -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans. <i>Clinical Infectious Diseases</i> , 2005, 41, 654-659.	2.9	640
8	β -D-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Clinical Infectious Diseases</i> , 2004, 39, 199-205.	2.9	610
9	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	4.6	586
10	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	4.6	528
11	Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3149-3154.	1.4	493
12	Combination Antifungal Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 693-715.	1.4	478
13	T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 892-899.	2.9	369
14	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	2.9	368
15	An insight into the antifungal pipeline: selected new molecules and beyond. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 719-727.	21.5	360
16	Amphotericin B: Time for a New "Gold Standard". <i>Clinical Infectious Diseases</i> , 2003, 37, 415-425.	2.9	350
17	Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 271-276.	1.3	325
18	Correlation between E-Test, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and Voriconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1647-1651.	1.4	221

#	ARTICLE	IF	CITATIONS
19	Invasive candidiasis in the intensive care unit. <i>Critical Care Medicine</i> , 2006, 34, 857-863.	0.4	217
20	In Vitro Antifungal Susceptibilities of <i>Trichosporon</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1144-1146.	1.4	184
21	Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against <i>Candida</i> and <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3475-3482.	1.8	174
22	Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. <i>Medical Mycology</i> , 2005, 43, 235-243.	0.3	165
23	Invasive Mycoses: Diagnostic Challenges. <i>American Journal of Medicine</i> , 2012, 125, S14-S24.	0.6	162
24	Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 143-147.	1.4	153
25	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226.	2.9	142
26	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018, 66, 1678-1686.	2.9	129
27	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017, 43, 1225-1238.	3.9	123
28	Differences in beta-glucan levels in culture supernatants of a variety of fungi. <i>Medical Mycology</i> , 2006, 44, 267-272.	0.3	121
29	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive <i>Candida</i> Infections: The ACTIVE Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1981-1989.	2.9	120
30	Clinical breakpoints for voriconazole and <i>Candida</i> spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 330-343.	0.8	117
31	(1,3)- β -D-Glucan as a Prognostic Marker of Treatment Response in Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2012, 55, 521-526.	2.9	116
32	Invasive Candidiasis in Immunocompromised Hospitalized Patients. <i>Archives of Medical Research</i> , 2005, 36, 660-671.	1.5	105
33	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011, 54, 46-51.	1.8	98
34	Prospective Survey of (1 \rightarrow 3)- β -Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting. <i>Journal of Clinical Microbiology</i> , 2011, 49, 58-61.	1.8	96
35	What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 808-819.	3.9	90
36	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	1.9	83

#	ARTICLE	IF	CITATIONS
37	In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1912-1915.	1.4	82
38	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	4.6	80
39	Early treatment of candidemia in adults: a review. <i>Medical Mycology</i> , 2011, 49, 113-120.	0.3	78
40	In Vitro Synergy Testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against <i>Aspergillus</i> spp. and <i>Fusarium</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3572-3574.	1.4	76
41	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e3647-e3655.	2.9	75
42	Coronavirus Disease 2019-associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.4	75
43	In Vitro Activities of Investigational Triazoles against <i>Fusarium</i> Species: Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Test Results. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3298-3300.	1.4	74
44	Cost of a Ventilator-Associated Pneumonia in a Shock Trauma Intensive Care Unit. <i>Surgical Infections</i> , 2005, 6, 65-72.	0.7	74
45	New approaches to the risk of <i>Candida</i> in the intensive care unit. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 533-537.	1.3	73
46	Tigecycline: a critical safety review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 335-342.	1.0	70
47	Current Options in Antifungal Pharmacotherapy. <i>Pharmacotherapy</i> , 2008, 28, 614-645.	1.2	68
48	Effects of Serum on In Vitro Susceptibility Testing of Echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4214-4216.	1.4	67
49	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 115.	2.6	63
50	Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 541-544.	1.1	58
51	Drugs in Clinical Development for Fungal Infections. <i>Drugs</i> , 2017, 77, 1505-1518.	4.9	58
52	Pharmacokinetic Evaluation of Single-Dose Intravenous Daptomycin in Patients with Thermal Burn Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1891-1893.	1.4	57
53	Deeply invasive candidiasis. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 821-835.	1.9	55
54	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3056-3062.	1.3	54

#	ARTICLE	IF	CITATIONS
55	Correlation of Clinical Outcomes with β -Glucan Levels in Patients with Invasive Candidiasis. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2104-2106.	1.8	51
56	Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3324-3327.	1.8	49
57	Invasive Fungal Infections in the Intensive Care Unit. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 475-487.	1.9	49
58	Liposuction for protease-inhibitor-associated lipodystrophy. <i>Lancet</i> , The, 1999, 353, 1244.	6.3	47
59	Successful Use of Amphotericin B Lipid Complex in the Treatment of Cryptococcosis. <i>Clinical Infectious Diseases</i> , 2005, 40, S409-S413.	2.9	46
60	Invasive Candidiasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 003-012.	0.8	45
61	Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 46, 49-54.	0.8	44
62	Editorial Commentary: Candida glabrata and FKS Mutations: Witnessing the Emergence of the True Multidrug-Resistant Candida. <i>Clinical Infectious Diseases</i> , 2013, 56, 1733-1734.	2.9	43
63	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx200.	0.4	43
64	In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical Candida Isolates. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1406-1412.	1.8	41
65	Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing <i>Candida</i> spp. by the CLSI M27-A2 Standard Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4175-4177.	1.4	40
66	Correlation between Microdilution, E-test, and Disk Diffusion Methods for Antifungal Susceptibility Testing of Posaconazole against Candida spp.. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2105-2108.	1.8	39
67	Clinical Characteristics and Predictors of Adverse Outcome in Adult and Pediatric Patients With Healthcare-Associated Ventriculitis and Meningitis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw077.	0.4	39
68	Multilaboratory Testing of Two-Drug Combinations of Antifungals against <i>Candida albicans</i> , <i>Candida glabrata</i> , and <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1543-1548.	1.4	38
69	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to <i>Candida parapsilosis</i> : a retrospective observational cohort study of the Mycoses Study Group (MSG-12): Table A1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3536-3539.	1.3	37
70	Contemporary Treatment and Outcomes of Zygomycosis in a Non-oncologic Tertiary Care Center. <i>Archives of Medical Research</i> , 2007, 38, 90-93.	1.5	35
71	Neurocysticercosis and HIV infection: Report of two cases and review. <i>World Neurosurgery</i> , 1996, 45, 57-61.	1.3	34
72	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018, 61, 518-533.	1.8	32

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3151-3153.	1.4	31
74	Surveillance of <i>Candida</i> spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals. <i>PLoS ONE</i> , 2014, 9, e97325.	1.1	30
75	Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of <i>Candida krusei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1500-1502.	1.4	28
76	Effect of the Echinocandin Caspofungin on Expression of <i>Candida albicans</i> Secretory Aspartyl Proteinases and Phospholipase In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3096-3100.	1.4	26
77	Associations between antibiotic use and changes in susceptibility patterns of in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 346-351.	1.1	26
78	Early antifungal intervention strategies in ICU patients. <i>Current Opinion in Critical Care</i> , 2010, 16, 465-469.	1.6	26
79	Syscan3, a Kit for Detection of Anti- <i>Candida</i> Antibodies for Diagnosis of Invasive Candidiasis. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4834-4835.	1.8	25
80	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018, 61, 420-429.	1.8	25
81	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	25
82	Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2617-2632.	0.9	24
83	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018, 61, 485-497.	1.8	24
84	Therapy of common superficial fungal infections. <i>Dermatologic Therapy</i> , 2004, 17, 517-522.	0.8	23
85	Fatal Amphotericin B Overdose Due to Administration of Nonlipid Formulation Instead of Lipid Formulation. <i>Pharmacotherapy</i> , 2005, 25, 426-428.	1.2	21
86	Investigational Agents for the Treatment of Resistant Yeasts and Molds. <i>Current Fungal Infection Reports</i> , 2021, 15, 104-115.	0.9	18
87	In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of <i>Candida</i> in the Presence of Antifungals. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	17
88	Seroprevalence of <i>Strongyloides stercoralis</i> and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012-2017). <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	17
89	Differential Antifungal Activity of Isomeric Forms of Nystatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2781-2786.	1.4	16
90	Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?. <i>Critical Care</i> , 2011, 15, 189.	2.5	15

#	ARTICLE	IF	CITATIONS
91	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on <i>Candida</i> bloodstream infection mortality, a retrospective analysis. <i>BMC Infectious Diseases</i> , 2017, 17, 753.	1.3	15
92	Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2020, 49, 77.	0.9	15
93	The Role of In Vitro Susceptibility Testing in the Management of <i>Candida</i> and <i>Aspergillus</i> . <i>Journal of Infectious Diseases</i> , 2017, 216, S452-S457.	1.9	14
94	A Risk Score for Fluconazole Failure among Patients with Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	12
95	Activity of Anidulafungin in a Murine Model of <i>Candida krusei</i> Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)- β -D-Glucan Levels. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1639-1641.	1.4	11
96	Point-Counterpoint: Should Serum β -D-Glucan Testing Be Used for the Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia?. <i>Journal of Clinical Microbiology</i> , 2019, 58, .	1.8	11
97	Progressive Dispersion of Azole Resistance in <i>Aspergillus fumigatus</i> : Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an <i>A. fumigatus</i> Strain with a <i>cyp51A</i> TR ₄₆ Y121F M172I T289A Allele. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	10
98	Screening donors for COVID-19 convalescent plasma. <i>Transfusion</i> , 2021, 61, 1047-1052.	0.8	8
99	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non- <i>A. fumigatus</i>): A multicentre, non-interventional registry study. <i>Mycoses</i> , 2022, 65, 186-198.	1.8	7

100

#	ARTICLE	IF	CITATIONS
109	Antifungal and Antiviral Therapy. , 2008, , 1089-1109.		2
110	Antifungal Susceptibility Testing: Evolution, Indications, and Role in Clinical Practice. Current Treatment Options in Infectious Diseases, 2015, 7, 155-162.	0.8	2
111	Epidemiology and Management of Candidiasis in Solid Organ Transplant Recipients. Current Fungal Infection Reports, 2016, 10, 147-152.	0.9	2
112	Anidulafungin: a new addition to the antifungal armamentarium. Therapy: Open Access in Clinical Medicine, 2007, 4, 125-132.	0.2	1
113	Neonatal Fungal Infections. , 2008, , 262-278.		1
114	Invasive Candidiasis in the Intensive Care Unit. Hospital Practice (1995), 2010, 38, 82-91.	0.5	1
115	High-Dose Caspofungin is Safe for Adult Patients with Invasive Candidiasis. Current Fungal Infection Reports, 2011, 5, 1-2.	0.9	1
116	369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis. Open Forum Infectious Diseases, 2018, 5, S144-S145.	0.4	1
117	Reprocessing N95s with hydrogen peroxide vaporization: A robust system from collection to dispensing. American Journal of Infection Control, 2021, 49, 508-511.	1.1	1
118	Candidemia: An Infection Prevention Issue?. Clinical Infectious Diseases, 2021, 73, 697-698.	2.9	1
119	Furuncular myiasis in a traveller to West Africa. Journal of Travel Medicine, 2021, 28, .	1.4	1
120	Neonatal Fungal Infections. , 2012, , 287-302.		1
121	Invasive Yeast Infections. Infectious Disease and Therapy, 2007, , 221-238.	0.0	1
122	Fungal and Parasitic Infections. , 2009, , 113-134.		1
123	Prophylaxis for Candida in the intensive care unit patient. Current Fungal Infection Reports, 2008, 2, 69-73.	0.9	0
124	Can fungal biomarkers be used to improve antifungal therapy in the intensive care unit?. Current Fungal Infection Reports, 2009, 3, 147-151.	0.9	0
125	Don't Pace Right Past the Sink: Electrophysiology Sterility Practices in the Face of Absent Guidelines. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
126	A marginal structural approach to measuring the comparative effectiveness of echinocandins Versus fluconazole therapy for the treatment of adult candidemia (MSG-12). Open Forum Infectious Diseases, 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
127	Epidemiology and Natural History of Non-Tuberculous Mycobacterial Surgical Sites Infections. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
128	Fungal Diagnostics: A Practical Approach. Current Clinical Microbiology Reports, 2016, 3, 103-110.	1.8	0
129	40 years of medical mycology at JAC. Journal of Antimicrobial Chemotherapy, 2016, 71, 3327-3329.	1.3	0
130	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. Open Forum Infectious Diseases, 2017, 4, S52-S52.	0.4	0
131	2045. Pitfalls in the Use of MALDI TOF Mass Spectrometry for the Identification of Problematic Yeast Isolates from a Historical Collection. Open Forum Infectious Diseases, 2018, 5, S596-S597.	0.4	0
132	Prevention and Treatment of Yeast and Endemic Fungal Infections. , 2019, , 179-199.		0
133	Measles or Not Measles? That is the Question!. Open Forum Infectious Diseases, 2020, 7, ofaa311.	0.4	0
134	The New Medical Mycology. Infectious Disease Clinics of North America, 2021, 35, xiii-xiv.	1.9	0
135	New Developments in Diagnostics and Management of Invasive Candidiasis. , 0, , 443-448.		0